1 Report Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type: 2020 VS 2026 1.2.2 Vitamin E & Pioglitazone 1.2.3 Obeticholic Acid (OCA) 1.2.4 Elafibranor 1.2.5 Selonsertib & Cenicriviroc 1.3 Market by Application 1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026 1.3.2 Hospital Pharmacy 1.3.3 Online Provider 1.3.4 Retail Pharmacy 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Perspective (2015-2026) 2.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Growth Trends by Regions 2.2.1 Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions: 2015 VS 2020 VS 2026 2.2.2 Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Share by Regions (2015-2020) 2.2.3 Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026) 2.3 Industry Trends and Growth Strategy 2.3.1 Market Trends 2.3.2 Market Drivers 2.3.3 Market Challenges 2.3.4 Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Market Size 3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Revenue (2015-2020) 3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Players (2015-2020) 3.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue 3.4 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio 3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019 3.5 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Area Served 3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service 3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Drugs Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Type (2015-2026) 4.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Type (2015-2020) 4.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Type (2021-2026) 5 Non-Alcoholic Steatohepatitis (NASH) Drugs Breakdown Data by Application (2015-2026) 5.1 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Historic Market Size by Application (2015-2020) 5.2 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Application (2021-2026) 6 North America 6.1 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026) 6.2 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) 6.3 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) 6.4 North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020) 6.4.1 United States 6.4.2 Canada 7 Europe 7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026) 7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) 7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) 7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020) 7.4.1 Germany 7.4.2 France 7.4.3 U.K. 7.4.4 Italy 7.4.5 Russia 7.4.6 Nordic 7.4.7 Rest of Europe 8 China 8.1 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026) 8.2 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) 8.3 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) 8.4 China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (2015-2020) 8.4.1 China 8.4.2 Japan 8.4.3 South Korea 8.4.4 Southeast Asia 8.4.5 India 8.4.6 Australia 8.4.7 Rest of Asia-Pacific 9 Japan 9.1 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026) 9.2 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) 9.3 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) 9.4 Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020) 9.4.1 Mexico 9.4.2 Brazil 10 Southeast Asia 10.1 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (2015-2026) 10.2 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) 10.3 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) 10.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (2015-2020) 10.4.1 Turkey 10.4.2 Saudi Arabia 10.4.3 UAE 10.4.4 Rest of Middle East & Africa 11 Key Players Profiles 11.1 AstraZeneca 11.1.1 AstraZeneca Company Details 11.1.2 AstraZeneca Business Overview 11.1.3 AstraZeneca Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.1.4 AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020)) 11.1.5 AstraZeneca Recent Development 11.2 Conatus Pharmaceuticals 11.2.1 Conatus Pharmaceuticals Company Details 11.2.2 Conatus Pharmaceuticals Business Overview 11.2.3 Conatus Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.2.4 Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.2.5 Conatus Pharmaceuticals Recent Development 11.3 Enzo Biochem 11.3.1 Enzo Biochem Company Details 11.3.2 Enzo Biochem Business Overview 11.3.3 Enzo Biochem Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.3.4 Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.3.5 Enzo Biochem Recent Development 11.4 Galmed Pharmaceuticals 11.4.1 Galmed Pharmaceuticals Company Details 11.4.2 Galmed Pharmaceuticals Business Overview 11.4.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.4.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.4.5 Galmed Pharmaceuticals Recent Development 11.5 Genfit 11.5.1 Genfit Company Details 11.5.2 Genfit Business Overview 11.5.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.5.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.5.5 Genfit Recent Development 11.6 Gilead 11.6.1 Gilead Company Details 11.6.2 Gilead Business Overview 11.6.3 Gilead Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.6.4 Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.6.5 Gilead Recent Development 11.7 Horizon Pharma 11.7.1 Horizon Pharma Company Details 11.7.2 Horizon Pharma Business Overview 11.7.3 Horizon Pharma Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.7.4 Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.7.5 Horizon Pharma Recent Development 11.8 Immuron 11.8.1 Immuron Company Details 11.8.2 Immuron Business Overview 11.8.3 Immuron Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.8.4 Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.8.5 Immuron Recent Development 11.9 Intercept Pharmaceuticals 11.9.1 Intercept Pharmaceuticals Company Details 11.9.2 Intercept Pharmaceuticals Business Overview 11.9.3 Intercept Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.9.4 Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.9.5 Intercept Pharmaceuticals Recent Development 11.10 Novo Nordisk 11.10.1 Novo Nordisk Company Details 11.10.2 Novo Nordisk Business Overview 11.10.3 Novo Nordisk Non-Alcoholic Steatohepatitis (NASH) Drugs Introduction 11.10.4 Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) 11.10.5 Novo Nordisk Recent Development 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Disclaimer 13.3 Author Details

List of Tables Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth Rate by Type (US$ Million): 2020 VS 2026 Table 3. Key Players of Vitamin E & Pioglitazone Table 4. Key Players of Obeticholic Acid (OCA) Table 5. Key Players of Elafibranor Table 6. Key Players of Selonsertib & Cenicriviroc Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Growth by Application (US$ Million): 2020 VS 2026 Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (US$ Million): 2020 VS 2026 Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Regions (2015-2020) (US$ Million) Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2015-2020) Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Forecasted Market Size by Regions (2021-2026) (US$ Million) Table 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026) Table 13. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Market Trends Table 14. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Drivers Table 15. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Challenges Table 16. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Restraints Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue by Players (2015-2020) (US$ Million) Table 18. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players (2015-2020) Table 19. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019) Table 20. Global Non-Alcoholic Steatohepatitis (NASH) Drugs by Players Market Concentration Ratio (CR5 and HHI) Table 21. Key Players Headquarters and Area Served Table 22. Key Players Non-Alcoholic Steatohepatitis (NASH) Drugs Product Solution and Service Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Type (2015-2020) Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2015-2020) Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size Share by Application (2021-2026) Table 30. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020) Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020) Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020) Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020) Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 37. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020) Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020) Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020) Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020) Table 42. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 43. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020) Table 44. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 45. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020) Table 46. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Region (US$ Million) (2015-2020) Table 47. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Region (2015-2020) Table 48. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 49. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020) Table 50. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 51. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020) Table 52. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020) Table 53. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020) Table 54. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Type (2015-2020) (US$ Million) Table 55. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type (2015-2020) Table 56. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Application (2015-2020) (US$ Million) Table 57. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application (2015-2020) Table 58. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size by Country (US$ Million) (2015-2020) Table 59. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Country (2015-2020) Table 60. AstraZeneca Company Details Table 61. AstraZeneca Business Overview Table 62. AstraZeneca Product Table 63. AstraZeneca Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 64. AstraZeneca Recent Development Table 65. Conatus Pharmaceuticals Company Details Table 66. Conatus Pharmaceuticals Business Overview Table 67. Conatus Pharmaceuticals Product Table 68. Conatus Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 69. Conatus Pharmaceuticals Recent Development Table 70. Enzo Biochem Company Details Table 71. Enzo Biochem Business Overview Table 72. Enzo Biochem Product Table 73. Enzo Biochem Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 74. Enzo Biochem Recent Development Table 75. Galmed Pharmaceuticals Company Details Table 76. Galmed Pharmaceuticals Business Overview Table 77. Galmed Pharmaceuticals Product Table 78. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 79. Galmed Pharmaceuticals Recent Development Table 80. Genfit Company Details Table 81. Genfit Business Overview Table 82. Genfit Product Table 83. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 84. Genfit Recent Development Table 85. Gilead Company Details Table 86. Gilead Business Overview Table 87. Gilead Product Table 88. Gilead Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 89. Gilead Recent Development Table 90. Horizon Pharma Company Details Table 91. Horizon Pharma Business Overview Table 92. Horizon Pharma Product Table 93. Horizon Pharma Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 94. Horizon Pharma Recent Development Table 95. Immuron Business Overview Table 96. Immuron Product Table 97. Immuron Company Details Table 98. Immuron Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 99. Immuron Recent Development Table 100. Intercept Pharmaceuticals Company Details Table 101. Intercept Pharmaceuticals Business Overview Table 102. Intercept Pharmaceuticals Product Table 103. Intercept Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 104. Intercept Pharmaceuticals Recent Development Table 105. Novo Nordisk Company Details Table 106. Novo Nordisk Business Overview Table 107. Novo Nordisk Product Table 108. Novo Nordisk Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) (US$ Million) Table 109. Novo Nordisk Recent Development Table 110. Research Programs/Design for This Report Table 111. Key Data Information from Secondary Sources Table 112. Key Data Information from Primary Sources List of Figures Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Type: 2020 VS 2026 Figure 2. Vitamin E & Pioglitazone Features Figure 3. Obeticholic Acid (OCA) Features Figure 4. Elafibranor Features Figure 5. Selonsertib & Cenicriviroc Features Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Application: 2020 VS 2026 Figure 7. Hospital Pharmacy Case Studies Figure 8. Online Provider Case Studies Figure 9. Retail Pharmacy Case Studies Figure 10. Non-Alcoholic Steatohepatitis (NASH) Drugs Report Years Considered Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size (US$ Million), YoY Growth 2015-2026 Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions: 2020 VS 2026 Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Regions (2021-2026) Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market Share by Players in 2019 Figure 15. Global Top Non-Alcoholic Steatohepatitis (NASH) Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Drugs as of 2019 Figure 16. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Drugs Revenue in 2019 Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 18. United States Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 19. Canada Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 20. Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 21. Germany Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 22. France Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 23. U.K. Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 24. Italy Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 25. Russia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 26. Nordic Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 27. Rest of Europe Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 28. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 29. China Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 30. Japan Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 31. South Korea Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 32. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 33. India Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 34. Australia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 35. Rest of Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 36. Latin America Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 37. Mexico Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 38. Brazil Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 39. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 40. Turkey Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 41. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 42. UAE Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 43. Rest of Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Drugs Market Size YoY Growth (2015-2026) & (US$ Million) Figure 44. AstraZeneca Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 45. Conatus Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 46. Enzo Biochem Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 47. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 48. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 49. Gilead Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 50. Horizon Pharma Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 51. Immuron Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 52. Intercept Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 53. Novo Nordisk Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Drugs Business (2015-2020) Figure 54. Bottom-up and Top-down Approaches for This Report Figure 55. Data Triangulation Figure 56. Key Executives Interviewed

AstraZeneca Conatus Pharmaceuticals Enzo Biochem Galmed Pharmaceuticals Genfit Gilead Horizon Pharma Immuron Intercept Pharmaceuticals Novo Nordisk